$325.07
+13.38 (+4.29%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NTRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 26 observational · 1 with posted results
Held by 18 tracked-famous managers (Duquesne Family Office LLC, COATUE MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, MAVERICK CAPITAL LTD, D. E. Shaw & Co., Inc., +13 more) · FINRA short interest 4.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 70 sells · government filings 180d: 0 congress / 2 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNCT07214532Invasive Disease-Free SurvivalOpen-label · Treatment | Not applicable | Recruiting | Device: ctDNA-Guided Treatment Strategy | Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement) | 725 | 2037-11-15 | in 4,105 d | 2026-08-13 |
| Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| Signatera Assessment in Early-Stage Endometrial CancerNCT07339384Recurrence Free Survival (RFS)Randomized · Double-masked · Treatment | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | Endometrial Cancer | 1,010 | Oct 2034 | ≤ 2,994 d | 2026-06-17 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization.Randomized · Open-label · Treatment | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)NCT07763197observationalNumber of Completed Participants with Blood, Urine and Residual Tissue Specimens Collected | — | Recruiting | — | Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer | 400 | Jul 2032 | ≤ 2,172 d | 2026-08-13 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886observationalPrimary Outcome - Blood and Residual Tissue Specimen Collection from 160 Completed Participants for Blood-Based Cancer Monitoring and Detection and Cancer Assay Development. | — | Recruiting | — | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Transformed Follicular Lymphoma, Follicular Lymphoma Grade 3B, Follicular Lymphoma, Anaplastic Large Cell Lymphoma | 200 | Apr 2032 | ≤ 2,080 d | 2026-08-06 |
| Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal CancerNCT07565857Disease Free Survival (DFS)Randomized · Open-label · Treatment | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | Gastric-Esophageal Cancer | 1,000 | Sep 2028 | ≤ 772 d | 2026-05-04 |
| Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)NCT07718633Tier 1: Compare the number of randomized participants who experienced death related to allograft, using a win ratio hierarchical endpointRandomized · Open-label · Treatment | Not applicable | Not yet recruiting | Diagnostic test: Prospera Immunosuppression Optimization | Kidney Transplant, Immunosuppresion | 750 | Dec 2027 | ≤ 498 d | 2026-07-22 |
| Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)NCT07046585observationalPrimary Outcome | — | Recruiting | — | Colo-rectal Cancer | 25,000 | 2027-07-10 | in 324 d | 2025-12-12 |
| EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)NCT06808880observationalPerformance of sgNIPT assay in the detection of primary four autosomal recessive disorders | — | Recruiting | Device: Single-gene Noninvasive Prenatal Testing (sgNIPT) | Single Gene NIPT | 4,000 | Apr 2027 | ≤ 253 d | 2026-05-04 |
| A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial BiopsyNCT06414603Primary Clinical EndpointRandomized · Open-label · Diagnostic | Not applicable | Active, not recruiting | Diagnostic test: The Prospera™ Test | Heart Transplant Failure and Rejection | 250 | Feb 2027 | ≤ 192 d | 2026-02-27 |
| Prospera Test Evaluation in Cardiac Transplant (ProTECT)NCT05205551observationalPrimary Endpoints: | — | Active, not recruiting | — | Heart Transplant Rejection | 411 | 2026-10-31 | in 72 d | 2025-05-22 |
| The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)NCT04091984observationalEfficiency of biopsies | — | Active, not recruiting | Diagnostic test: Prospera | Kidney Transplant Rejection | 5,000 | 2026-10-01 | in 42 d | 2024-08-06 |
| LAMBDA 002 (Lung Registry) StudyNCT05170425observationalPercent of donor-derived cell-free DNA (ddcfDNA) measured via the Prospera test | — | Active, not recruiting | Device: Prospera | Lung Transplant Rejection | 154 | Aug 2026 | ≤ 11 d | 2025-05-22 |
| Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer DetectionNCT06620627observationalPrimary Objective | — | Recruiting | — | Colorectal Cancer Screening | 5,000 | 2025-07-31 | — | 2025-01-29 |
| BESPOKE Study of ctDNA Guided Therapy in Colorectal CancerNCT04264702observationalExamine the impact of SIGNATERA™ on adjuvant treatment decisions | — | Unknown status | — | Colorectal Cancer, Colon Cancer | 1,788 | Sep 2025 | — | 2023-12-12 |
| Renasight Clinical Application, Review and Evaluation (RenaCARE) StudyNCT05846113Test Positive Prevalence: The frequency of positive test results across the entire cohort and within different categories of kidney disorders will be analyzed.Open-label · Diagnostic | Not applicable | Unknown status | Diagnostic test: Renasight | Kidney Diseases | 1,720 | Aug 2025 | — | 2023-09-28 |
| Donor-Derived Cell-free DNA to DETect REjection in Cardiac TransplantationNCT05081739Demonstrate the use of Prospera for post-transplant surveillance is non-inferior to the current standard of care, EMB surveillance, with respect to the primary composite endpoint.Randomized · Single-masked · Prevention | Not applicable | Withdrawnsponsor's stated reason: Sponsor made decision to pause study while it was still in development phase. The FDA and IRB approval process had not been completed. No sites were activated. No subjects had been recruited for this study. | Diagnostic test: Prospera Transplant Assessment · Procedure: Endomyocardial biopsy | Heart Transplant Failure and Rejection | 0 | Jan 2025 | — | 2024-04-03 |
| Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart TransplantationNCT05309382observationalPrimary Molecular Endpoint | — | Completed | Diagnostic test: Prospera | Heart Transplant | 147 | 2024-10-02actual | — | 2024-10-29 |
| Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA DetectionNCT03984747observationalTo develop an assay to detect allograft rejection status in transplant patients involving amplification of donor-derived cell-free DNA from donor recipient blood. | — | Completed | — | Transplant Rejection, Allograft Rejection, Complications | 110 | 2024-08-23actual | — | 2025-03-18 |
| BESPOKE Study of ctDNA Guided ImmunotherapyNCT04761783observationalExamine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy | — | Completed | — | Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer | 290 | 2023-12-31actual | — | 2024-08-15 |
| Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin PregnanciesNCT05004337observationalDevelop a new algorithm and methodology that will measure fetal fraction and distinguish between the DT (demised/non-viable twin) and living twin (LT) in dizygotic twins (DZ) with a single LT. | — | Completed | — | Vanishing Twin, Trisomy 21, Trisomy 13, Trisomy 18 | 136 | 2023-11-29actual | — | 2026-08-17 |
| Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.NCT05312814observationalAssess clinical utility of combining NIPT-based zygosity measurements with ultrasound chorionicity assessments for the management of twin pregnancies. | — | Completed | — | Twin to Twin Transfusion Syndrome, Pregnancy Complications, Multiple Gestation; Maternal Care | 137 | 2023-05-15actual | — | 2024-09-26 |
| Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal BloodNCT01852708observationalSensitivity and Specificity of testing | — | Completed | — | Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities, Microdeletion Syndromes | 1,059 | Oct 2020actual | — | 2020-12-30 |
| SNP-based Microdeletion and Aneuploidy RegisTry (SMART)NCT02381457observational22q11.2 Snp-based non-invasive prenatal screening test performance, including positive predictive value (PPV), specificity, and sensitivity | — | Completed | — | 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome | 20,960 | Jun 2020actual | — | 2021-01-29 |
| Natera Ovarian Cancer Detection AssayNCT03485651observationalCompare ctDNA from benign ovarian masses and confirmed ovarian cancers | — | Terminatedsponsor's stated reason: Poor accrual | — | Adnexal Mass | 12 | 2019-11-01actual | — | 2020-02-06 |
| Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNANCT02109770observationalSensitivity and Specificity of the test to diagnose chromosomal microdeletions and aneuploidy in a fetus | — | Completed | — | Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities | 216 | Jun 2019actual | — | 2019-08-26 |
| Multiple Gestation StudyNCT02278536observationalThe primary outcome will be to confirm the diagnostic capability of NATUS risk results classified as positive result for aneuploidy, negative result for aneuploidy or 'no call.' | — | Completed | — | Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities | 354 | Mar 2019actual | — | 2019-08-26 |
| High Risk Multiple Gestation StudyNCT02278874observationalScreening capability of proprietary algorithm in the form of a risk results classified as positive result for aneuploidy, negative result for aneuploidy or 'no call.' | — | Completed | — | Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities | 99 | 2018-12-01actual | — | 2019-06-13 |
| Prenatal Non-invasive Aneuploidy Test Utilizing SNPs TrialNCT01545674observationalSensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y. | — | Terminatedsponsor's stated reason: Non-invasive Prenatal Screening CLIA test performance validated in other cohort. Decided samples not required, study aims achieved through other studies. | Procedure: Blood Draw | Trisomy 13, Trisomy 18, Trisomy 21, Aneuploidy | 937 | Apr 2014actual | — | 2023-03-23 |
| Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)NCT01023048Confirm diagnosis through prenatal diagnosis (CVS or amniocentesis)Open-label · Diagnostic | Not applicable | Completed | Other: preimplantation diagnosis | Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) | 56 | Mar 2014actual | — | 2014-04-02 |
| Clinical Use of Parental Support To Detect Single Gene MutationsNCT01197872observationalConfirmation of diagnosis through prenatal diagnosis | — | Completed | Other: Preimplantation Genetic Diagnosis | Single Gene Disorders | 240 | Jun 2013actual | — | 2013-07-16 |
| Multi-disease Carrier Screening Test ValidationNCT01663584observational | — | Withdrawnsponsor's stated reason: Samples were not needed for test development, therefore subjects were not recruited or enrolled | Procedure: Blood draw | Spinal Muscular Atrophy (SMA), Carrier Screening, Genetic Testing | 0 | Jun 2013actual | — | 2013-07-16 |
| Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh TransferNCT01194531results2014-11-13Implantation RateRandomized · Open-label · Screening | Phase 4 | Terminatedsponsor's stated reason: Slow enrollment and Natera is transitioning to a new PGS testing platform. | Device: 24 Chromosome Aneuploidy Screening with Parental Support | Preimplantation Gentic Screening (PGS), In Vitro Fertilization (IVF), Preimplantation Genetic Diagnosis (PGD) | 59 | Apr 2013actual | — | 2014-11-25 |
| Non-invasive Prenatal Diagnostic Validation StudyNCT01574781observationalFetal chromosome abnormality from a maternal plasma sample | — | Completed | Procedure: Blood draw, Cheek swab/Saliva Sampling | Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations, Other Microdeletions | 1,781 | Apr 2013actual | — | 2013-07-02 |
| Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic TestingNCT01546324observationalCollection of 500 maternal blood samples to be used for development of non-invasive prenatal diagnostic testing. | — | Completed | Procedure: Blood draw | Pregnancy Following IVF With PGS/PGD | 16 | May 2012actual | — | 2013-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19